image

Investors

Corporate Profile

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates that can modulate proteins within the cell.

Week of April 22, 2024

Date Requested Closing Price Volume Split Adjustment Factor Open Price Day High Day Low
April 22, 2024 $13.58 574,496 1:1 $13.69 $14.10 $13.30
April 23, 2024 $14.13 895,076 1:1 $13.59 $14.44 $13.59
April 24, 2024 $13.75 519,873 1:1 $14.05 $14.42 $13.52

NOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date shown. The Split Adjustment Factor is a cumulative factor which encapsulates all splits since the date shown. The closing price is not necessarily indicative of future price performance.

Data Provided by Refinitiv. Minimum 15 minutes delayed.